RecruitingPhase 2NCT07179055
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
Sponsor
Vanda Pharmaceuticals
Enrollment
160 participants
Start Date
Oct 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Be at least 18 years of age of either gender and any race.
- Provide written informed consent and sign the HIPAA form.
- Be willing and able to follow all instructions and attend all study visits.
Exclusion Criteria1
- Use of any of the disallowed medications during the washout and study period.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVSJ-110
ophthalmic solution
DRUGPlacebo
ophthalmic solution
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07179055
Related Trials
Detection and Optimization of Treatment of Severe Cases of Dry Eye Disease
NCT075549111 location
Single-Arm Study of a Treatment for Dry Eye in People Who Struggle to Wear Contact Lenses
NCT075106201 location
PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes
NCT073669441 location
Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy
NCT073297121 location
SAS 1: Develop Ocular Disease (OSD) Diagnostic, Algorithms, and Management Protocols for Cataract Surgery
NCT073232641 location